Does epirubicin affect left ventricular systolic performance in oncologic patients?

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Epirubicin is a commonly used chemotherapy agent for various cancers.
• Cardiotoxicity is a known side effect of anthracycline chemotherapy.
• The impact of lower epirubicin doses on cardiac function requires further investigation.

Purpose of the Study:

• To evaluate left ventricular diastolic and systolic functions in patients treated with lower total doses of epirubicin.
• To assess the effects of epirubicin on cardiac performance using Doppler echocardiography.

Main Methods:

• Doppler echocardiography was performed on 17 patients treated with epirubicin (up to 450 mg/m(2)) and 29 controls.
• Left ventricular diastolic function was assessed by transmitral flow (E wave, A wave, E/A ratio, PHT, IVRT).
• Left ventricular systolic function was evaluated by ejection fraction (EF).

Main Results:

• Epirubicin treatment significantly decreased Emax and increased A wave, resulting in a subunitary E/A ratio.
• Prolonged pressure half time (PHT) and iso-volumic relaxation time (IVRT) indicated impaired diastolic function.
• Left ventricular systolic function, assessed by EF, was not significantly altered, although it was lower in the epirubicin group.

Conclusions:

• Lower total doses of epirubicin impair left ventricular diastolic performance in cancer patients.
• The observed diastolic dysfunction is attributed to reduced left ventricular compliance.
• Doppler echocardiography is a valuable tool for detecting early cardiac changes associated with epirubicin therapy.